TODAY'S MARKET INTELLIGENCE
Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data, Personalized Cancer Vaccine Meets Goal
English summary
On Aug. 19, 2026, Moderna's personalized cancer vaccine met its primary endpoint in a Phase 3 melanoma trial. The company and Merck plan an FDA submission, sending Moderna shares up 177% and highlighting mRNA technology's promise in oncology.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence